1.Study on serum estradiol, FSH, LH concentration of menopausal women in Hanoi city
Journal of Medical Research 1999;9(1):13-20
The study was carried out in Hoankiem and Socson district in Hanoi city. In each area, 160 women were selected and divided in to 4 groups: the menopause of 5 years, >5-10 years, >10 years and groups of 25-39 year old. Vein blood were taken for the measurement of serum estradiol, FSH, LH concentration. The results showed that: Serum estradiol concentration significantly decreased in postmenopausal women compared with women at reproductive age and no difference between the menopausal groups. These values in Hoankiem women were higher than that in Socson women, specially with the menopause of 5 years. Serum FSH and LH concentration significantly increased in the menopausal period. While FSH concentration did not change during menopause time, LH concentration showed a tendency to decrease. Serum FSH concentration in the Hoankiem women was higher than this in Socson ones whereas serum concentration was lower
Menopause
;
Menotropins
;
serum
;
women
2.Efficacy and safety of human chorionic gonadotropin combined with human menopausal gonadotropin and a gonadotropin-releasing hormone pump for male adolescents with congenital hypogonadotropic hypogonadism.
Ying LIU ; Xiao-Ya REN ; Ya-Guang PENG ; Shao-Ke CHEN ; Xin-Ran CHENG ; Miao QIN ; Xiao-Ling WANG ; Yan-Ning SONG ; Li-Jun FAN ; Chun-Xiu GONG
Chinese Medical Journal 2021;134(10):1152-1159
BACKGROUND:
Compared to adult studies, studies which involve the treatment of pediatric congenital hypogonadotropic hypogonadism (CHH) are limited and no universal treatment regimen is available. The aim of this study was to evaluate the feasibility of human chorionic gonadotropin (hCG)/human menopausal gonadotropin (hMG) therapy for treating male adolescents with CHH.
METHODS:
Male adolescent CHH patients were treated with hCG/hMG (n = 20) or a gonadotropin-releasing hormone (GnRH) pump (n = 21). The treatment was divided into a study phase (0-3 months) and a follow-up phase (3-12 months). The testicular volume (TV), penile length (PL), penis diameter (PD), and sex hormone levels were compared between the two groups. The TV and other indicators between the groups were analyzed using a t-test (equal variance) or a rank sum test (unequal variance).
RESULTS:
Before treatment, there was no statistical difference between the two groups in terms of the biochemistry, hormones, and other demographic indicators. After 3 months of treatment, the TV of the hCG/hMG and GnRH groups increased to 5.1 ± 2.3 mL and 4.1 ± 1.8 mL, respectively; however, the difference was not statistically significant (P > 0.05, t = 1.394). The PL reached 6.9 ± 1.8 cm and 5.1 ± 1.6 cm (P < 0.05, t = 3.083), the PD reached 2.4 ± 0.5 cm and 2.0 ± 0.6 cm (P < 0.05, t = 2.224), respectively, in the two groups. At the end of 6 months of treatment, biomarkers were in normal range in the two groups. Compared with the GnRH group, the testosterone (T) level and growth of PL and PD were significantly greater in the hCG/hMG group (all P < 0.05). While the TV of both groups increased, the difference was not statistically significant (P > 0.05, t = 0.314). After 9 to 12 months of treatment, the T level was higher in the hCG/hMG group. Other parameters did not exhibit a statistical difference.
CONCLUSIONS:
The hCG/hMG regimen is feasible and effective for treating male adolescents with CHH. The initial 3 months of treatment may be a window to optimally observe the strongest effects of therapy. Furthermore, results from the extended time-period showed positive outcomes at the 1-year mark; however, the long-term effectiveness, strengths, and weaknesses of the hCG/hMG regimen require further research.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT02880280; https://clinicaltrials.gov/ct2/show/NCT02880280.
Adolescent
;
Adult
;
Child
;
Chorionic Gonadotropin/therapeutic use*
;
Gonadotropin-Releasing Hormone
;
Humans
;
Hypogonadism/drug therapy*
;
Male
;
Menotropins/therapeutic use*
;
Spermatogenesis
;
Testosterone
3.Effect of traditional Chinese herbs combined with low dose human menopausal gonadotropin applied in frozen-thawed embryo transfer.
Hui-qin ZHANG ; Bei YAN ; Hong-xin ZHAO ; Dun-yu GU ; Xiao-feng JIA ; Lin CAO ; Lei WANG ; Hui-juan SHI
Chinese journal of integrative medicine 2006;12(4):244-249
OBJECTIVETo assess embryo implantation rate (IR) and pregnancy rate (PR) in women who received Bushen Wengong Decoction (BSWGD), a Chinese herbal formula, combined with low dose of human menopausal gonadotropin (hMG) prior to frozen-thawed embryo transfer (FET).
METHODSA total of 262 subjects (674 transferred embryos) who received FET were analyzed retrospectively. In them, 122 women were under 30 years old, 106 between 30 - 35 years and 32 over 35 years. The 85 subjects with normal ovulation were assigned to Group A, the natural menstruation cycling group, on whom no pre-transfer treatment was applied. The other 177 subjects with abnormal ovulation were assigned to Group B, and subdivided, according to the pre-transfer treatment they received, into three groups, Group B1 (50 cases) received BSWGD, Group B2 (58 cases) received hMG and Group B3 (69 cases) received both BSWGD and low dose hMG. The IR and PR of FET in the four groups were compared, and the effect of the embryo cryotime on PR of FET were compared also. Besides, the influencing factors to FET were analyzed.
RESULTSIR and PR were significantly higher in all age sects of Group B3 than those in Group A, showing significant difference (P< 0.05). IR and PR in subjects in age sects of <30 years and > 35 years in group B3 were significantly higher than those in Group B1 ( P<0.05), but no significant difference was shown in the two parameters between Group B 2 and Group B3 (P>0.05). PR in the subjects who received embryos with cryo-time of > 200 days was significantly lower than that in those with cryo-time of < 100 days ( P<0.05). Embryo cryo-time, endometrial thickness, use of BSWGD and use of hMG were of significance in FET ( P 0.05).
CONCLUSIONA programmed cycle of BSWGD combined with low dose of hMG could improve the embryo IR and PR of FET. Embryo cryo-time, endometrial thickness, and the use of BSWGD and hMG are of significance for FET.
Adult ; Cryopreservation ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; administration & dosage ; Embryo Transfer ; Female ; Humans ; Menotropins ; administration & dosage ; Pregnancy ; Pregnancy Rate ; Retrospective Studies
4.Experimental study on effect of erzhi tiangui recipe on quality of oocyte in mice.
Fang LIAN ; Zheng-gao SUN ; Jian-wei ZHANG ; Ning ZHANG ; Yanhe LIU ; Lin MU ; Peng ZHANG
Chinese Journal of Integrated Traditional and Western Medicine 2004;24(7):625-627
OBJECTIVETo observe the effect of Erzhi Tiangui recipe (ETR) on quality of oocyte in the process of external fertilization and embryo-transplantation.
METHODSEighty mice were randomly divided into 4 groups, Group A treated with ETR plus human menopausal gonadotropin (HMG), Group B with ETR, Group C with HMG and Group D with normal saline. Ovulation test and cleavage test were conducted to observe the effect of treatment on quality of oocytes.
RESULTSThe difference on ovulation number between Group A and C was insignificant, but the difference in comparison between the two groups was significant in aspects of oocyte morphological scoring, fertilization rate and cleavage rate (P<0.05).
CONCLUSIONETR could play its effect synergistically with Western medicine, and raise the quality of oocytes.
Animals ; Cell Division ; drug effects ; Drug Synergism ; Drugs, Chinese Herbal ; pharmacology ; Embryo Transfer ; Female ; Fertilization ; drug effects ; Fertilization in Vitro ; drug effects ; Menotropins ; pharmacology ; Mice ; Oocytes ; drug effects ; physiology ; Ovulation Induction ; Random Allocation
5.Trigger effect of hMG and hCG in the treatment of unexplainable non-obstructive azoospermia.
Hao-Rui HU ; Hong-Chuan NIE ; Wei-Min YANG ; Yuan SUN ; Hui HUANG ; Fang-Gang XIE
National Journal of Andrology 2017;23(9):813-816
Objective:
To investigate whether the trigger effect of human menopausal gonadotropins (hMG) and human chorionic gonadotropins (hCG) attributes to the treatment of unexplainable non-obstructive azoospermia (NOA).
METHODS:
We retrospectively analyzed the clinical data about 282 cases of unexplainable NOA treated in the Maternity and Child Health Hospital of Guizhou Province from January 2010 to May 2017. All the patients underwent trigger treatment by intramuscular injection of hMG at 75 IU 3 times a week for 2 weeks, followed by hCG at 2 000 IU twice a week for another 2 weeks, and meanwhile took vitamin E, Levocarnitine and Tamoxifen as an adjunctive therapy. The treatment lasted 3-12 months.
RESULTS:
Fifty-eight of the 255 patients that completed the treatment were found with sperm in the semen after treatment, all with severe oligoasthenospermia. Forty-seven of the 58 cases received assisted reproductive technology (ART), of which 18 achieved clinical pregnancy. Semen centrifugation revealed no sperm in the other cases, of which 6 were found with epididymal sperm at epididymal and testicular biopsy after treatment and 3 of them achieved clinical pregnancy after ART. Sperm was found in the semen or at epididymal or testicular biopsy in 64 of the patients after treatment, with an effectiveness rate of 25.1%.
CONCLUSIONS
Trigger treatment by injection of hMG and hCG combined with adjunctive oral medication has a certain effect on unexplainable NOA.
Azoospermia
;
drug therapy
;
Chorionic Gonadotropin
;
therapeutic use
;
Drug Administration Schedule
;
Epididymis
;
Female
;
Fertility Agents, Male
;
therapeutic use
;
Humans
;
Injections, Intramuscular
;
Male
;
Menotropins
;
therapeutic use
;
Pregnancy
;
Pregnancy Rate
;
Reproductive Techniques, Assisted
;
Retrospective Studies
;
Sperm Retrieval
;
statistics & numerical data
;
Spermatozoa
;
Testis
6.Modified super-long down-regulation protocol improved the outcome of in vitro fertilization-embryo transfer in infertile patients.
Fei GONG ; Yi TANG ; Hong ZHANG ; Guangxiu LU
Journal of Central South University(Medical Sciences) 2009;34(3):185-189
OBJECTIVE:
To investigate the outcome of in vitro fertilization and embryo transfer (IVF-ET) in special infertile patients following modified super-long down-regulation protocol combined with human menopausal gonadotropin (HMG) stimulation.
METHODS:
Ninety-nine special patients (42 with endometriosis, 35 with PCOS, and 22 with insufficient down-regulation) who underwent modified super-long down-regulation protocol in 2008 were retrospectively analyzed. Gonadotropin releasing hormone analogues (GnRHa, 1.5 mg) was injected intramuscularly in mid-luteal phase twice and HMG was started 25 days later after the second GnRHa injection. Conventional IVF-ET was performed as routine procedure. The clinical outcomes were compared with those of 122 similar patients in the same period.
RESULTS:
After modified super-long down-regulation, (1) in endometriosis patients, the average gonadotropin (Gn) used was (32.33 +/- 15.11) ampoules, duration of medication was (10.57 +/- 1.88) days, the progesterone (P) level on hCG day was (0.78 +/- 0.44) microg/L, and the clinical pregnancy rate (CPR) was 73.8%; (2) in PCOS patients, the average Gn used was (28.57 +/- 12.07) ampoules, the duration of medication was (11.71 +/- 2.07) days, the P level at hCG day was (0.65 +/- 0.39) microg/L, and the clinical pregnancy rate was 65.7%; (3) in insufficient down-regulation patients, the average Gn used was (26.22 +/- 12.07) ampoules, the duration of medication was (10.01 +/- 1.77) days, the P level at hCG day was (0.71 +/- 0.50) microg/L, and the clinical pregnancy rate was 72.7%. Compared with patients using regular down-regulation protocol, the clinical pregnancy rate was improved significantly and the cost decreased obviously. The clinical pregnancy rate significantly improved compared with that of routine long down-regulation groups.
CONCLUSION
Revised super-long protocol plus HMG is a cost-effective controlled ovary hyperstimulation (COH) regimen for infertile patients with endometriosis, PCOS and insufficient down-regulation.
Adult
;
Embryo Transfer
;
methods
;
Endometriosis
;
complications
;
Female
;
Fertility Agents, Female
;
therapeutic use
;
Fertilization in Vitro
;
methods
;
Gonadotropin-Releasing Hormone
;
agonists
;
therapeutic use
;
Humans
;
Infertility, Female
;
etiology
;
therapy
;
Menotropins
;
therapeutic use
;
Ovulation Induction
;
economics
;
methods
;
Polycystic Ovary Syndrome
;
complications
;
Pregnancy
;
Retrospective Studies
;
Treatment Outcome